Comparative Pharmacology
Head-to-head clinical analysis: LIDOPEN versus SYNERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOPEN versus SYNERA.
LIDOPEN vs SYNERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Tetracaine is an ester-type local anesthetic that similarly inhibits sodium channels. The combination provides local dermal anesthesia.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
Apply 1 patch (70 mg lidocaine and 70 mg tetracaine) to intact skin over the intended venipuncture site or superficial dermatologic procedure site 20-30 minutes prior to procedure; maximum 1 patch per procedure.
None Documented
None Documented
1.5–2 hours (terminal); prolonged in hepatic impairment
Lidocaine: 1.5–2 hours; prilocaine: 1–1.5 hours. Terminal half-life similar for both. Note: prolonged in hepatic impairment or neonates.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Renal excretion of lidocaine and prilocaine metabolites: lidocaine <10% unchanged, prilocaine negligible unchanged. Metabolites primarily renal.
Category C
Category C
Local Anesthetic
Local Anesthetic